Laura M. Hernández-Regino

Laura M. Hernández-Regino

Auto-generated profile, based on publicly available information

Laura M. Hernández-Regino

Laboratory of Pharmacology, National Institute of Pediatrics, Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2023 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
LTLuz-María Torres-Espíndola
Luz-María Torres-Espíndola
PPPerla-Lidia Pérez-Pineda
Perla-Lidia Pérez-Pineda
RORocío Ortiz-Butrón
Rocío Ortiz-Butrón
JMJuan Carlos Pérez De Marcos
Juan Carlos Pérez De Marcos
LHLaura M. Hernández-Regino
Laura M. Hernández-Regino
MTMarta Zapata Tarres
Marta Zapata Tarres
Background: Medulloblastomas (MB) are the most common malignant brain tumors in the pediatric age. In 2021, WHO categorized medulloblastomas into two groups: molecularly defined and histologically defined medulloblastomas. Molecularly defined medulloblastomas are divided into WNTactivated medulloblastoma, SHH-activated and TP53-wildtype medulloblastoma, SHH-activated, and TP53-mutant and non-WNT/non-SHH medulloblastoma, which include Group 3 (MYC) and Group 4 (CDK6 and MYCN). In this paper, we will focus on molecularly defined medulloblastomas. Objective: This paper aims to review the literature in order to describe the molecular structure of the medulloblastoma groups and to emphasize the importance of genetic predictors in medulloblastoma that can be used in clinical practice, either as a prognostic tool or as a therapeutic target in the future. Results: Each molecular subtype of medulloblastoma presents a different prognosis, and the molecular subtype with the best prognosis is medulloblastoma-activated WNT. It has even been observed that a reduction in the intensity of the combined treatment does not modify the prognosis of the patients, resulting in even fewer adverse effects due to the treatment. On the other hand, it was observed that the subtypes with the worst prognosis are medulloblastomas with activated MYC and medulloblastomas with activated SHH and mutated TP53, due to their high capacity to metastasize or to their radio-resistance. However, a new target therapy has emerged that could help improve the prognosis in these patients. Conclusion: The deeper knowledge of the molecular pathways involved in the appearance and progression of medulloblastomas will allow us to offer a prognosis at the time of diagnosis and more specific treatments through the development of the targeted therapy.